Tumor
Markers
Tumors are common pathological conditions in clinical practice and may affect tissues and organs throughout the body. They are associated with conditions such as gastrointestinal, hepatic, pulmonary, and reproductive system malignancies. Tumor progression may occur with or without obvious clinical symptoms and is often accompanied by elevated tumor marker levels in blood. By measuring tumor marker concentrations, KSB tumor marker assays support the evaluation, screening, monitoring, and management of tumor-related conditions.
Tumor markers are biologically derived substances that are characteristically associated with malignant tumors and the complex molecular processes underlying cancer development. These substances may be produced directly by tumor cells, expressed at abnormally high levels due to genetic or regulatory alterations within malignant tissues, or generated by the host organism as part of an immune, inflammatory, or metabolic response to tumor presence and progression. In clinical oncology, tumor markers encompass a broad range of biomolecules, including proteins, glycoproteins, enzymes, hormones, antigens, receptors, and nucleic acid fragments, all of which may reflect abnormal cellular proliferation and tumor biology.
The presence and concentration of tumor markers often correlate with clinically relevant parameters such as tumor burden, disease stage, histological type, metastatic spread, and therapeutic response. As a result, tumor markers are widely applied in oncology practice as supportive tools for early detection strategies, prognostic assessment, treatment monitoring, and post-therapy surveillance. While most tumor markers do not exhibit sufficient specificity or sensitivity to serve as standalone diagnostic criteria, their longitudinal measurement provides valuable insight into disease dynamics and patient response to treatment interventions such as surgery, chemotherapy, radiotherapy, targeted therapies, and immunotherapies.
Tumor markers can be detected in a range of biological samples, including blood, serum, plasma, urine, stool, and other body fluids, depending on the clinical relevance and intended diagnostic application of each marker. Their measurement is most commonly performed using immunological techniques, which provide the sensitivity and specificity required for reliable clinical interpretation. Among these, immunochromatographic lateral flow assays are widely used due to their simplicity, rapid turnaround time, and suitability for POCT. These assays enable fast and convenient detection of tumor-associated biomarkers, supporting screening, diagnostic, and treatment monitoring in both laboratory and decentralized healthcare settings.
In particular, immunochromatographic lateral flow assays represent a rapid and user-friendly platform for tumor marker detection at the point of care. KSB tumor marker assays enable qualitative (FOB) or quantitative (all the other assays) analysis within minutes, supporting timely clinical decision-making in hospitals, laboratories, and decentralized healthcare settings. By combining antibody-based recognition with membrane-driven capillary flow, lateral flow technology allows for efficient and cost-effective screening and monitoring of tumor-associated biomarkers. As such, tumor marker testing remains an essential component of modern in-vitro diagnostics, supporting improved patient management and more responsive oncology care pathways.
Explore
Your
Options
深圳市康生保
生物技术有限公司
深圳市宝安区
福海 街道
新和 社区 安达
电子厂区3栋2楼
518103
+86 0755 27417763
info@ksbbiotech.com